- Price
- $404.85
- Day
- -0.73%
- Mkt Cap
- $218.50B
- 52W Range
- $269.77 – $418.40
- Volume
- 2.44M
- Beta
- 0.40
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.
Read full article
Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.
Read full article
Deep Dive - Snail Inc
Read full article
Amgen Inc. delivered a strong Q2 results, beating revenue and EPS estimates, and raised full-year guidance by $1 billion and $0.50, respectively. Despite $7 billion in LOE headwinds, Amgen's commercial portfolio—driven by Repatha, Uplizna, Evenity, Tezspire, and Imdelltra—continues to outperform expectations. Key pipeline catalysts, including MariTide and olpasiran phase 3 readouts, are expected in 2027–2028, with near-term pipeline news flow remaining light.
Read full article
Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares rose about 4% on Wednesday after the biotechnology company reported second quarter 2026 results that topped Wall Street expectations, supported by higher revenue and growth across its portfolio of medicines. The company reported adjusted earnings per share of $6.29 for the quarter, ahead of analyst estimates of roughly $5.60 to $5.62.
Read full article
Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares rose about 4% on Wednesday after the biotechnology company reported second quarter 2026 results that topped Wall...
Read full article
Total Revenues: Exceeded $10 billion, a 10% year-over-year increase.Product Sales Growth: 22 products delivered double-digit sales growth; 17 products annualize
Read full article
THOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2026.
Read full article
Amgen NASDAQ: AMGN reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spending on late-stage clinical programs and manufacturing capacity.
Read full article
Amgen Inc (AMGN) released its 8-K filing on August 4, 2026, detailing its financial results for the second quarter of 2026. The biotechnology giant reported a 1
Read full article
THOUSAND OAKS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the Amgen data breach.
Read full article
Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the company continues to develop experimental weight-loss drug MariTide.
Read full article